These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 21538327)

  • 1. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
    Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A
    Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
    Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
    Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.
    Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E
    Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
    Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M;
    Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
    Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
    Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of morbidity and mortality of systemic sclerosis in Canada.
    Al-Dhaher FF; Pope JE; Ouimet JM
    Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
    Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
    Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.